US EditionResults From the AENEAS2 Trial Point to a New Frontline Treatment Option for NSCLC - ILCN.org (ILCN/WCLC)
Summary by ILCN.org (ILCN/WCLC)
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Results From the AENEAS2 Trial Point to a New Frontline Treatment Option for NSCLC - ILCN.org (ILCN/WCLC)
Scientists behind the phase III randomized, controlled AENEAS2 clinical trial said their results point to a new front-line treatment option for patients with locally advanced or metastatic EGFR-mutated non-small-cell lung cancer (NSCLC). Shun Lu, MD, PhD The trial’s principal investigator, Shun Lu, MD, PhD, said that aumolertinib with platinum-pemetrexed chemotherapy demonstrated a statistically significant and clinically meaningful improvement…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
